These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 23880735)

  • 1. Single-nucleotide polymorphisms in reductase genes are not associated with response to daunorubicin-based remission induction.
    Lubieniecka JM; Liu J; Graham J; Heffner D; Reid R; Hogge D; Grigliatti TA; Riggs WK
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1918-20. PubMed ID: 23880735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-nucleotide polymorphisms in aldo-keto and carbonyl reductase genes are not associated with acute cardiotoxicity after daunorubicin chemotherapy.
    Lubieniecka JM; Liu J; Heffner D; Graham J; Reid R; Hogge D; Grigliatti TA; Riggs WK
    Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2118-20. PubMed ID: 23001242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.
    Devillier R; Bertoli S; Prébet T; Huguet F; Etienne A; Charbonnier A; Rey J; Delabesse E; D'Incan E; Huynh A; Blaise D; Récher C; Vey N
    Am J Hematol; 2015 Feb; 90(2):E29-30. PubMed ID: 25363834
    [No Abstract]   [Full Text] [Related]  

  • 4. [The role of daunorubicin in induction therapy for adult acute myeloid leukemia].
    Usui N; Dobashi N; Asai O; Yano S; Kato A; Osawa H; Uno S; Katori M; Nagamine M; Yahagi Y; Yamaguchi Y; Saito T; Kasama K; Takei Y; Ogihara A; Yamazaki H; Kobayashi T; Tajima N; Ogawa M; Kuraishi Y
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1152-9. PubMed ID: 10945010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
    Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
    Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
    Dobashi N; Usui N; Yano S; Yahagi Y; Takei Y; Sugiyama K; Takahara S; Ogasawara Y; Yamaguchi Y; Saito T; Yokoyama H; Aiba K
    Jpn J Clin Oncol; 2011 Jun; 41(6):820-4. PubMed ID: 21415001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose versus standard-dose daunorubicin in induction therapy for young patients with de novo acute myeloid leukaemia: a meta-analysis of randomised trials.
    Su L; Zhu X; Gao S; Li W; Liu X; Tan Y
    J Chemother; 2016 Apr; 28(2):123-8. PubMed ID: 27104964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.
    Hiddemann W; Martin WR; Sauerland CM; Heinecke A; Büchner T
    Leukemia; 1990 Mar; 4(3):184-8. PubMed ID: 2314117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.
    Varatharajan S; Abraham A; Zhang W; Shaji RV; Ahmed R; Abraham A; George B; Srivastava A; Chandy M; Mathews V; Balasubramanian P
    Eur J Clin Pharmacol; 2012 Dec; 68(12):1577-86. PubMed ID: 22562609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia.
    Varatharajan S; Panetta JC; Abraham A; Karathedath S; Mohanan E; Lakshmi KM; Arthur N; Srivastava VM; Nemani S; George B; Srivastava A; Mathews V; Balasubramanian P
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1051-1058. PubMed ID: 27738808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients.
    Wang YH; Takanashi M; Tsuji K; Tanaka N; Shiseki M; Mori N; Motoji T
    Leuk Res; 2009 Jul; 33(7):902-7. PubMed ID: 19185918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia.
    Trifilio S; Zhou Z; Mehta J; Czerniak C; Pi J; Greenberg D; Koslosky M; Pantiru M; Altman J
    Leuk Res; 2013 Aug; 37(8):868-71. PubMed ID: 23726414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
    Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
    Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review.
    Zeichner SB; Alghamdi S; Elhammady G; Poppiti RJ
    Asian Pac J Cancer Prev; 2014; 15(4):1603-9. PubMed ID: 24641375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of acute leukemia in the adult. Role of anthracyclines].
    Gisselbrecht C; Lepage E; Lenoble M; Marty M; Boiron M
    Pathol Biol (Paris); 1987 Jan; 35(1):69-74. PubMed ID: 3550615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous intravenous administration of daunorubicin and cytarabine for remission induction of poor risk acute myelogenous leukaemias and myelodysplastic syndromes.
    Bär BM; de Witte T; de Pauw BE; Haanen C
    Neth J Med; 1990 Feb; 36(1-2):19-24. PubMed ID: 2314517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.